SlideShare a Scribd company logo
1 of 63
Download to read offline
Panorama of actions patient organisations
can take in pharmacovigilance
EURODIS conference - capacity building for expert patients and researchers
Mitul Jadeja June 2018
Mitul Jadeja - EURODIS PV training
This presentation
How to familiarise
yourself with the
reporting methods of
NCAs and
regulatory outputs
How to explain PV
to patients and
engage
Planning a
campaign
Measuring success
Examples of some
initiatives and
campaigns
encourage patient
reporting
Practical tools you
can use
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Why do we need pharmacovigilance?
Clinical trials Real world setting
“the science and activities
relating to the detection,
assessment,
understanding and
prevention of adverse
effects or any other drug-
related problem”
0
20
40
60
80
100
120
1 10 100 1000 10000
Frequency of ADR
TimetoonsetofADR
Mapping safety & need for PhV
Known at licensing
• Pre-marketing data have important limitations
• Pre-clinical data: low predictive value
Clinical trial data provide
provisional evidence of
safety but:
- too small
- limited duration
- limited populations
- not representative of
real world
Establishment of drug safety monitoring
Mitul Jadeja - EURODIS PV training
Anything to do with
a medicine I’ve
been given that
causes me harm
‘Suspected’ ADR or
‘side effect’
report to the
national ADR
reporting system
What’s in a definition?
• Adverse reaction; adverse drug reaction (ADR), Adverse effect, Undesirable effect: A response to a medicinal product
which is noxious and unintended [DIR 2001/83/EC Art 1(11)]. Response in this context means that a causal relationship
between a medicinal product and an adverse event is at least a reasonable possibility. Adverse reactions may arise from
use of the product within or outside the terms of the marketing authorisation or from occupational exposure [DIR
2001/83/EC Art 101(1)]. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse,
abuse and medication errors.
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf&rct=j&frm=1&q=&esr
c=s&sa=U&ved=0CBoQFjABahUKEwjolcC8yLzIAhUClA0KHXLNDOU&usg=AFQjCNHt2ArigMn1WpHp2KejiS76RDNYxA
• GVP Module VI.B.6.3 -medication error: ‘any unintended error in the prescribing, dispensing or administration of a
medicinal product while in the control of the healthcare professional, patient or consumer’ - this definition is focused on the
management and reporting of adverse reactions to medicinal products and does not cover all stages of the medication use
process where an error may occur and where there is an adverse reaction, e.g. preparation for administration.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000570.jsp
Mitul Jadeja - EURODIS PV training
Do you know your national
medicines regulators?
• EMA has a list of NCAs:
http://www.ema.europa.eu/em
a/index.jsp?curl=pages/medici
nes/general/general_content_
000155.jsp
• National PV centres
• RMCs
Mitul Jadeja - EURODIS PV training
www.adrreports.eu
• Accessible in multiple
languages
• List of national
medicines regulatory
authorities in the EEA
• Information on
reporting
• Access reports
submitted to
Eudravigilance
• Like iDAPs
• Online
• App
• clinical systems
• Paper
• phone Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV traininghttp://www.adrreports.eu/docs/ADR_reporting_FINAL_EN.pdf
Mitul Jadeja - EURODIS PV training
Black Triangle Scheme ▼
• Risk benefit profile knowledge limited - Report all ADRs
• Materials: video and printable leaflets in many languages
http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/genera
l_content_000586.jsp&mid=WC0b01ac05807257a3
When does a medicine have a ▼?
• new active substance;
• biological medicine, such as a vaccine or a medicine derived
from plasma (blood);
• given a conditional approval (where the company that
markets the medicine must provide more data about it) or
approved under exceptional circumstances (where there are
specific reasons why the company cannot provide a
comprehensive set of data);
• the company is required to carry out additional studies: for
instance, to provide more data on long-term use of the
medicine, or on a rare side effect seen during clinical trials.
• Other medicines can also be placed under additional
monitoring, based on a decision by the Agency's
Pharmacovigilance Risk Assessment Committee (PRAC).
Mitul Jadeja - EURODIS PV training
Cystadrops (mercaptamine)
• for treatment of cystinosis
• typically diagnosed prior
to age 2.
• genetic metabolic disease
that causes an amino
acid, cystine, to
accumulate in various
organs of the body.
Cystine crystals
accumulate in the
kidneys, eyes, liver,
muscles, pancreas, brain,
and white blood cells.
• MA issued, +ve COMP
opinion, Jan 17
Mitul Jadeja - EURODIS PV training
iDAP: interactive drug analysis profile
Mitul Jadeja - EURODIS PV training
Information on orphan designations
Mitul Jadeja - EURODIS PV training
Accessing outputs of regulatory action
• Patient Safety warnings
• Product information (MA):
SmPCs & PILs, and labelling
• EU Public Assessment Reports
• Safety Communications e.g. Medicine
Alerts and DHCPs
• Rare disease designations
• Pubic hearings
• Committee information
• Additional Monitoring lists
• Risk Management Plans
• Educational material – HPRA
• Newsletters – e.g. Drug Safety Update
• Sign up to updates and RSS feeds
http://www.ema.europa.eu/ema/index.jsp?curl=p
ages/home/Home_Page.jsp&mid=
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Pharmacovigilance legislation
- ‘take all appropriate measures’
“Directive 2010/84/EU… Article 102. The
Member States shall:
….take all appropriate measures to encourage
patients, doctors, pharmacists and other
health-care professionals to report suspected
adverse reactions to the national competent
authority [MHRA]; for these tasks, consumer
organisations, patients organisations and
healthcare professionals organisations may be
involved as appropriate.”
Preaching to the converted? Need to raise general awareness
Mitul Jadeja - EURODIS PV training
Responding to change: drivers
for initiatives & campaigns
– Protecting public health and patients
– ADR statistics
– Underreporting & impact of ADRs
– pharmacovigilance legislation implications:
• Definition of ADR
• EU wide patient reporting
• Additional Monitoring - ▼
• Support for strengthening ADR reporting;
product information messages
– HMA support: same 4 pillars
– Independent review e.g. HTA, Avery report
recommendations
– Maintaining/strengthening ‘regularory position’
– SCOPE and ICMRA
Directive 2010/84/EU and Regulation 1235/2010
Mitul Jadeja - EURODIS PV training
Patient Information Leaflet
For medicinal products subject to additional monitoring ONLY:
The black symbol and the statements should only appear immediately after the declaration of the
name of the medicine. The black symbol shall be a black inverted equilateral triangle: the symbol
shall be proportional to the font size of the subsequent standardised text and in any case each
side of the triangle shall have a minimum length of 5 mm. For the purpose of preparing the
product information annexes please use the Black Triangle as presented in the template.
‘▼ This medicine is subject to additional monitoring. This will allow quick identification
of new safety information. You can help by reporting any side effects you may get. See
the end of section 4 for how to report side effects.’
For ALL medicinal products:
The following sub-heading should appear at the end of section 4
‘Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card
Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more
information on the safety of this medicine.’
Mitul Jadeja - EURODIS PV training
Patient reporting in EV – a measure of patient
engagement? Workshop on measuring the
impact of PV activities
• Patients are more
likely to report ADRs
for substances for
genitourinary system
and systemic
hormonal preparations
than HCPs – aligned
with the results for
Indications (2009-15)
• 13/20 most frequently
reported terms are
identical as HCPs.
• Marin Banovac
6/12/16
KISSS – keep it simple, short and specific
• Experienced a side effect? Please report! 
• Always read the PIL (lists known side effects)
• Speak to a healthcare professional for advice
– Explain the benefit  & to public health
– Don’t delay, report today ‐ don’t wait for someone else to 
report it
– Only a suspicion is needed, even if you
• don’t see a connection between the drug & ADR
• think the ADR doesn’t last for long, isn’t severe, or you think it‘s from 
long term use
• Don’t worry about ▼, off‐label use, med errors….. Avoid scare tactics Mitul Jadeja – EURODIS PV training
22
Mitul Jadeja - EURODIS PV training
Developing clear messages based on
research
Patients
• Your report is important to help make medicines
safer
• Only a suspicion is needed to report
• How to report
• Always read the Patient Information Leaflet
supplied with your medicine for more
information on side effects
• Speak to your HCP for further advice
Parents
• Reports from parents like you are very useful.
• Parents know their child better than anyone and
can tell us about things that healthcare
professionals can’t.
• We want parents to send reports even if they
only have slight concerns about a medicine –
you don’t need to be certain that a medicine has
actually caused a side effect to send a report.
• Reports are confidential. We won’t share the
information on your report with your child’s
doctor if you don’t want us to.
Consider integrating the following set of key messages for developing basic patient messages for promotion purposes
(from campaign material used):
Mitul Jadeja - EURODIS PV training
Proactive pyramid of engagement
opportunities
• Offer a menu to NCA’s
• Empowerment vs Engagement
• Consider:
‐ Budget
‐ Resource
‐ Time to engage
‐ Training
‐ Local vs national
‐ Helplines
‐ RMCs
‐ Registries
‐ MoUs
‐ Tenders
Decision 
making
Consulting
Committee
&
Management
Research & 
Project 
work
Social 
media
Forming 
formalised 
partnership 
&  
agreement Campaign 
work –
ADRs can 
be the first 
catalyst
Educational 
programmes
Educational 
materials
Mitul Jadeja - EURODIS PV training
EMA
model
Mitul Jadeja - EURODIS PV training
What impact can engagement provide?
• Patient/consumer perspective
• Patient concerns/questions
• Disease specific
• Appropriate language
– complicated, scientific terms, numbers, benefits, approval
• Understandable without source docs
• ‘Fresh eyes’
• Quality check
• Enhanced communication
• Effectiveness of messages
• Better outcomes
Planning a campaign
Mitul Jadeja - EURODIS PV training
Where do you begin?
Where are
you now?
Where do
you want to
be?
How are you
going to get
there?
(in relation to ADRs!)
Mitul Jadeja - EURODIS PV training
Where are you now?
• ADR statistics
– helps focus efforts
– example tables in guidance
• Stakeholder analysis
– helps shape strategy & messages
– basic stakeholder analysis
matrix in guidance
– Understand your audience
• Benchmarking
– focuses efforts, helps measure, an
engagement opportunity
– examples of through polls and surveys
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
patients pharmacists nurses doctors
‘Combined qualifications’ from
‘direct’ Yellow Cards reporting
2011 2012 2013 2014 2015 2016
Benchmarking questions
ADR reporting
Who would you report an unexpected
side effect with a medicine to? (Or
ADR if aimed at HCPs)
If a patient reports an ADR to you, to
whom or to which organisation would
you report it, if anyone?
Which, if any, of the following things
would help you to report ADRs?
Medicines Regulation
Who do you think regulates medicines to make sure they
work and are safe enough to use?
How much, if anything, would you say you know about
the way medicines are regulated?
Mitul Jadeja - EURODIS PV training
Where do you want to be?
• Across the national health service, where will you choose to raise
awareness levels? Why?FocusFocus
• What about patients? Their organisations?StakeholdersStakeholders
• How is your work related with other organisations or regulators?InteractionsInteractions
• What collaborations and partnerships can be formed?PartnershipsPartnerships
• What do you need to implement your strategy?ImplementationImplementation
• What does it look like? Can you compare before and after?Measuring successMeasuring success
• What can you do once for a lasting impact on ADR reporting and
your audiences?Sustainable effortsSustainable efforts
Mitul Jadeja - EURODIS PV training
What to measure?
Real impact is the number of suspected ADR reports
(consider measuring per population)
• Outputs – e.g. numbers of posters, books, leaflets, posters, partnerships etc.
• Key messages and out-takes – e.g. where to report, understanding of the
concept of reporting, understanding the value of reporting, the effect of reporting,
etc.
• Outcomes – changes in suspected ADR reporting numbers, changes in
behaviours, attitudes, opinions which can be measured.
• Examples from: GR, SE, ES, IS, MT, NL, FR, HR, DK, UK
Mitul Jadeja - EURODIS PV training
Working with stakeholders
• Improves the ability to reach target
audience
• Deliver messages effectively and reduces
message fatigue
• Provided potential additional opportunities
• Feedback on approach and effectiveness
• Cost effective
– Regional PV centres
– Academic organisations
– Professional bodies
– Hospitals
– Charities/voluntary organisations
– Government agencies
ADR
reports
ADR
reports
monitor numbers
before and after,
consider per x
population
monitor numbers
before and after,
consider per x
population
dashboards,
management
reports
dashboards,
management
reports
SignalsSignals
monitor numbers
before and after
monitor numbers
before and after
signal
dashboards,
PRAC signals,
regulatory action
signal
dashboards,
PRAC signals,
regulatory action
Attitudes
and
behaviour
Attitudes
and
behaviour
analyse changes
before and after
analyse changes
before and after
surveys, pols,
interviews,
workshops, focus
groups, action
plans
surveys, pols,
interviews,
workshops, focus
groups, action
plans
Social
media
Social
media
views, retweets,
likes, shares,
polls, follows,
followers, blogs,
RSS subscribers
views, retweets,
likes, shares,
polls, follows,
followers, blogs,
RSS subscribers
management
reports, simple
counts and
software tools
management
reports, simple
counts and
software tools
WebsiteWebsite
web analytics to
monitor trends
over time, site
search terms,
downloads,
views
web analytics to
monitor trends
over time, site
search terms,
downloads,
views
analytical
software such as
Google analytics,
Webtrends
analytical
software such as
Google analytics,
Webtrends
Measuring success: 1) Key areas 2) what
to measure 3) how to measure
1
2
3
Mitul Jadeja - EURODIS PV training
Key Activities
Mitul Jadeja - EURODIS PV training
Video and digital banners
Further embedding through
collaboration
Mitul Jadeja - EURODIS PV training
Challenges
• Time taken to engage with stakeholders & continuing engagement
• Multiple changes in staff
• Negotiation and influencing – low/no cost
• Measuring success - ‘some’ communications can be difficult to show
any immediate cultural changes
• Opinions and consensus - political
• Press work & Patient case studies
• Flexibility in approaches to working
Tools you can use
Mitul Jadeja - EURODIS PV training
SCOPE guidance
• Raising and Measuring Awareness
Levels for ADR Reporting Systems
through Campaigns and Regional
Monitoring Centres
• Contains huge annex of case
studies by country containing
materials
• e.g. ANSM call for
patients/organisations to report and
get involved in studies
Author: Mitul Jadeja
Mitul Jadeja - EURODIS PV training
SCOPE animation https://www.youtube.com/watch?v=3et5LdYLc8M
Mitul Jadeja - EURODIS PV training
Suspected side effect?
Mitul Jadeja - EURODIS PV training
• In UK, over 6K.
• Pilot findings
• Similar levels of reports of serious reactions
• Fewer reactions to black triangle drugs
• Less complete reports: but no difference in causality, or proportion of
unlabelled reactions
• More information on impact of ADRs on quality of life
• Low levels of consumer awareness of the YC Scheme
Reporting helps
Mitul Jadeja - EURODIS PV training
Essential Information
1. Suspect drug
2. Description of the side effect
3. Patient details
(e.g. age, sex, weight)
4. Reporter details
Additional Information
• Relevant past medical history
• Test results
• Whether reaction was serious
• Name and address of reporter
• * GP details
(patient’s consent required)
Important Information
• Dose and indication of the suspect
drug and dates of the treatment
• Dates the suspect reaction started
and stopped
• Outcome of the reaction
• Other drugs taken in the past 3
months prior to the reaction
Break down
reporting
Mitul Jadeja - EURODIS PV training
Use this crib sheet to help complete a Yellow Card if you suspect an
adverse drug reaction (ADR)
Adverse
Drug
Reaction
suspected?
www.mhra.gov.uk/yellowcard or App
Paper Yellow Cards available from:
back of the BNF, MHRA Commission on Medicines
(CHM) free phone: 0800 731 6789, ABPI medicines
compendium or MIMS Companion
Report it via a Yellow Card
The minimum information
needed for completing a
Yellow Card:
Additional information to supply
(this information helps assess the Yellow
Card):
Names of the medicine(s)
suspected to have caused the
reaction
Details of the suspect medicine(s) if available. For
example;
dose
start and stop dates
route of administration
Batch numbers especially for vaccines,
biosimilars and biological medicines
action taken with the drug - stopped, dose
change, restarted, none etc.
Suspected reaction(s)
Details of the reactions if available:
a brief description of reaction
diagnosis if relevant
start and stop dates of reaction
seriousness (use tick boxes on Yellow Card)
treatment given
reaction outcome
At least one patient identifier:
 Sex
 Age
 Weight
 initials
 local identifier
All should be completed if available
Any additional information you have:
relevant medical history
test results
other drugs taken in the last 3 months
if any rechallenge was performed
If it is a congenital abnormality, state all other
drugs taken during pregnancy and date of last
menstrual period
If no further information is available, please indicate
this on the Yellow Card
Reporter details:
Include your name, qualification
and full address
Do you suspect an adverse drug reaction?
Serious
reaction?
Involves a
medicine on
additional
monitoring
(▼)?
Unlisted
reaction
in product
information
Unsure
to report?
No
Involves a
child or
elderly
person?
ReportYes
No
No
No
No
ReportYes
ReportYes
ReportYes
ReportYes
Other PDFs with
info for patients on
the Yellow Card
website on what to
report and why –
applicable for all
reporting systems.
Mitul Jadeja - EURODIS PV training
Case studies are important
[Image from Arch Dis Child Fetal Neonatal Ed 2012;97:F64. doi:10.1136/adc.2011.215145]
• chlorhexidine antiseptic solution associated with
chemical burns
• review of OTC liquid codeine medicines for cough in children
• review of over-the-counter cough and cold medicines for use
in children
• oral iron products associated with hypersensitivity (allergic
type reactions)
• skin reactions associated with the use of aqueous cream in
children with eczema
• https://www.gov.uk/government/uploads/system/uploads/atta
chment_data/file/396811/Contribution_of_Yellow_Cards_to_i
dentifying_safety_issues.pdf
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Mobile Applications
• Secure – no
ADRs stored on
device
• View numbers of
YCs
• Simple to submit
updates to reports
• Allows viewing of
previous reports
via the app
• WEB-RADR
Mitul Jadeja - SCOPE EURODIS PV training
Mitul Jadeja - EURODIS PV training
Channels
and
Tactics
highlighted
Channels
and
Tactics
highlighted
Hungary
Interactive
presentations
Hungary
Interactive
presentations
Bulgaria
posters and
arguments
list
Bulgaria
posters and
arguments
list
Croatia
Radio &
Theatre
Croatia
Radio &
Theatre
Denmark
Learning
website with
videos
Denmark
Learning
website with
videos
Czech
Republic
Videos,
postcards &
posters
Czech
Republic
Videos,
postcards &
posters
Latvia
PV book
Latvia
PV book
United
Kingdom
online forum
for doctors
use of social
media and
digital banners
United
Kingdom
online forum
for doctors
use of social
media and
digital banners
Ireland
Congress
and special
award
Ireland
Congress
and special
award
Most successful campaigns
featured:
• forming long term sustainable
partnerships
• engagement with HCPs in a
familiar environment
• Distributed & online materials
• Press & media coverage
• Use of various forms of
collateral and channels
After these medicines, Doctor, I feel
better already but my wife says I have
a strange colour recently.
Hepatotoxicity is a possible side effect
of many medications
Mitul Jadeja - EURODIS PV training
Leaflets
Mitul Jadeja - EURODIS PV training
Videos from projects
https://www.youtube.com/watch?v=cRLHFKuNQEc http://greatdanefilm.dk/web/laeger/20102011bivirkning/
Mitul Jadeja - EURODIS PV training
Mitul Jadeja - EURODIS PV training
Special Populations
Mitul Jadeja - EURODIS PV training
WHO collateral
Mitul Jadeja - EURODIS PV training
• Maximising use of
social media
Mitul Jadeja - EURODIS PV training
• Using hash tags &
specificity
• #PV
• #drugsafety
• #patientsafety
• #ADRs
• #reportsideeffects…
Mitul Jadeja - EURODIS PV training
• Leverage
content across
platforms to
boost efficiency
& avoid content
duplication
Mitul Jadeja - EURODIS PV training
Take home messages
• Be proactive to promote and report suspected ADRs with patients
and your members. Social media is a powerful medium, use the
ready to use materials available to support tackle underreporting and
raising awareness.
• Keep is simple, short and specific
• Access regulatory outputs to engage with NCAs/patients
• Don’t hesitate to ask/offer support/guidance on materials /decisions
that you can input/develop/tailor to meet patient needs
• Consider the engagement pyramid – how can you help NCAs
understand your stakeholders and help shape direction of work and
decision making
Mitul Jadeja - EURODIS PV training
Reflections…
• When did you last discuss side effects with members?
• Have you surveyed them? What are their awareness levels?
▼? Have you done a SWOT or GAP analysis?
• How many side effects have you reported? How was the
experience? Did you feedback?
• What can you do to promote reporting?
• What are your messages?
• Which tools will you use? Are they the most effective?
• How will you stay up to date with latest info?
• How will you measure success?
• Social media – how active are you?
• Will you support future campaigns? Are you a patient QPPV?
Contacted your regulator?
• What else do you need to facilitate your important role in
patient safety?
Mitul Jadeja - EURODIS PV training
Thank you and questions?
Crown copyright 2018
• The views of the author are his own.
• The materials featured within these MHRA presentation notes and delegate pack are subject to Crown copyright
protection for this event. Any other copy or use of Crown copyright materials featured in this presentation, in any form or
medium, is subject to prior approval of the MHRA which has Delegated Authority from Her Majesty's Stationery Office
(HMSO) to administer Crown copyright for MHRA originated material. Applications should be in writing, clearly stating the
proposed use/reuse of the information, and should be sent to the MHRA at the following address:
Conference and Education Function
151 Buckingham Palace Road
London SW1W 9SZ
Fax 020 3080 6522
e-mail: speakers@mhra.gsi.gov.uk
• You may not sell or resell any information reproduced to any third party without prior agreement. The permission to
reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate
licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright
holders concerned

More Related Content

What's hot

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Pharmacovigilance - Patient Safety
Pharmacovigilance - Patient SafetyPharmacovigilance - Patient Safety
Pharmacovigilance - Patient SafetyAnastasios Baltzidis
 
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012kamynevy
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilancej8kinyua
 
Pharmacovigilance in real life may 12
Pharmacovigilance in real life   may 12Pharmacovigilance in real life   may 12
Pharmacovigilance in real life may 12Doctors.net.uk
 
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATION
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATIONFREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATION
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATIONPristyn Research Solutions
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINEsathishat9
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulationsUntil ROI
 
Pharmacovigilance (pvg) by dr.varun
Pharmacovigilance (pvg) by dr.varunPharmacovigilance (pvg) by dr.varun
Pharmacovigilance (pvg) by dr.varunvarunrmch
 
Pharmacovigilance a general overview most updated
Pharmacovigilance  a general overview  most updatedPharmacovigilance  a general overview  most updated
Pharmacovigilance a general overview most updatedpeter donik
 
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & ChallengesPharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challengespi
 
Pharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistPharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistDr. Ramesh Bhandari
 
European Clinical Trial Safety Focus
European  Clinical Trial Safety FocusEuropean  Clinical Trial Safety Focus
European Clinical Trial Safety FocusVaska Toné
 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisationSomya Solanki
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance pptPrasad Bhat
 
Pharmacovigilance Training
Pharmacovigilance TrainingPharmacovigilance Training
Pharmacovigilance TrainingSteve Jolley
 
Pharmacovigilance reporting - presentation MDR TB
Pharmacovigilance reporting - presentation MDR TB Pharmacovigilance reporting - presentation MDR TB
Pharmacovigilance reporting - presentation MDR TB Norah Oenga
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...Until ROI
 

What's hot (20)

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Pharmacovigilance - Patient Safety
Pharmacovigilance - Patient SafetyPharmacovigilance - Patient Safety
Pharmacovigilance - Patient Safety
 
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Materiovigilance ppt
Materiovigilance pptMateriovigilance ppt
Materiovigilance ppt
 
Pharmacovigilance in real life may 12
Pharmacovigilance in real life   may 12Pharmacovigilance in real life   may 12
Pharmacovigilance in real life may 12
 
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATION
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATIONFREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATION
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEW AND ITS PREPARATION
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINE
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
 
Pharmacovigilance (pvg) by dr.varun
Pharmacovigilance (pvg) by dr.varunPharmacovigilance (pvg) by dr.varun
Pharmacovigilance (pvg) by dr.varun
 
Pharmacovigilance a general overview most updated
Pharmacovigilance  a general overview  most updatedPharmacovigilance  a general overview  most updated
Pharmacovigilance a general overview most updated
 
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & ChallengesPharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challenges
 
Pharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistPharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacist
 
European Clinical Trial Safety Focus
European  Clinical Trial Safety FocusEuropean  Clinical Trial Safety Focus
European Clinical Trial Safety Focus
 
16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring Centre16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring Centre
 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisation
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance ppt
 
Pharmacovigilance Training
Pharmacovigilance TrainingPharmacovigilance Training
Pharmacovigilance Training
 
Pharmacovigilance reporting - presentation MDR TB
Pharmacovigilance reporting - presentation MDR TB Pharmacovigilance reporting - presentation MDR TB
Pharmacovigilance reporting - presentation MDR TB
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
 

Similar to panorama of actions patient organisations

TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA Australia
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance OverviewSivasankaranV
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxPankajKadyan5
 
Postmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaPostmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaTGA Australia
 
GPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaGPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaTGA Australia
 
Patient centered Pharmacovigilance .. .
Patient centered Pharmacovigilance     .. .Patient centered Pharmacovigilance     .. .
Patient centered Pharmacovigilance .. .ClinosolIndia
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaBishnu Koirala
 
Introduction on Pharmacovigilance.pptx
Introduction on Pharmacovigilance.pptxIntroduction on Pharmacovigilance.pptx
Introduction on Pharmacovigilance.pptxvedanshu malviya
 
Pharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidatesPharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidatesJonaid Ali
 
Global ADR Reporting Systems
Global ADR Reporting SystemsGlobal ADR Reporting Systems
Global ADR Reporting SystemsClinosolIndia
 
Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Consorci de Salut i Social de Catalunya
 
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsPresentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsTGA Australia
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 

Similar to panorama of actions patient organisations (20)

Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket Monitoring
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
 
Methods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptxMethods and Tools for ADR Reporting.pptx
Methods and Tools for ADR Reporting.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Postmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaPostmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in Australia
 
GPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaGPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in Australia
 
Pharmacovigilance AND HIPAA
Pharmacovigilance AND HIPAA Pharmacovigilance AND HIPAA
Pharmacovigilance AND HIPAA
 
Patient centered Pharmacovigilance .. .
Patient centered Pharmacovigilance     .. .Patient centered Pharmacovigilance     .. .
Patient centered Pharmacovigilance .. .
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koirala
 
Introduction on Pharmacovigilance.pptx
Introduction on Pharmacovigilance.pptxIntroduction on Pharmacovigilance.pptx
Introduction on Pharmacovigilance.pptx
 
Pharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidatesPharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidates
 
Global ADR Reporting Systems
Global ADR Reporting SystemsGlobal ADR Reporting Systems
Global ADR Reporting Systems
 
Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...
 
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reformsPresentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reforms
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Pharmacovigilance and adr
Pharmacovigilance and adrPharmacovigilance and adr
Pharmacovigilance and adr
 

More from EURORDIS Rare Diseases Europe (20)

Gene editing to treat cystic fibrosis_Vertex
Gene editing to treat cystic fibrosis_VertexGene editing to treat cystic fibrosis_Vertex
Gene editing to treat cystic fibrosis_Vertex
 
From Laboratory to Patient
From Laboratory to PatientFrom Laboratory to Patient
From Laboratory to Patient
 
Committee for Advanced Therapies
Committee for Advanced TherapiesCommittee for Advanced Therapies
Committee for Advanced Therapies
 
3b. Introductory Statistics - Julia Saperia
3b. Introductory Statistics - Julia Saperia3b. Introductory Statistics - Julia Saperia
3b. Introductory Statistics - Julia Saperia
 
3.nf
3.nf3.nf
3.nf
 
3.i
3.i3.i
3.i
 
2.it
2.it2.it
2.it
 
2.ab
2.ab2.ab
2.ab
 
1.3 df
1.3 df1.3 df
1.3 df
 
1.4 av
1.4 av1.4 av
1.4 av
 
2.it
2.it2.it
2.it
 
2.ab
2.ab2.ab
2.ab
 
1.2 fpr
1.2 fpr1.2 fpr
1.2 fpr
 
1.1 annaritamiccio
1.1 annaritamiccio1.1 annaritamiccio
1.1 annaritamiccio
 
1 engaging with ema methodology and support
1 engaging with ema methodology and support1 engaging with ema methodology and support
1 engaging with ema methodology and support
 
Chmp 2018 houyez
Chmp 2018 houyezChmp 2018 houyez
Chmp 2018 houyez
 
Cup case study
Cup case studyCup case study
Cup case study
 
Hta fhz
Hta fhzHta fhz
Hta fhz
 
Patients chmp 2018
Patients chmp 2018Patients chmp 2018
Patients chmp 2018
 
Vigilance 2018 final
Vigilance 2018 finalVigilance 2018 final
Vigilance 2018 final
 

Recently uploaded

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 

Recently uploaded (20)

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 

panorama of actions patient organisations

  • 1. Panorama of actions patient organisations can take in pharmacovigilance EURODIS conference - capacity building for expert patients and researchers Mitul Jadeja June 2018
  • 2. Mitul Jadeja - EURODIS PV training This presentation How to familiarise yourself with the reporting methods of NCAs and regulatory outputs How to explain PV to patients and engage Planning a campaign Measuring success Examples of some initiatives and campaigns encourage patient reporting Practical tools you can use Mitul Jadeja - EURODIS PV training
  • 3. Mitul Jadeja - EURODIS PV training Why do we need pharmacovigilance? Clinical trials Real world setting “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug- related problem”
  • 4. 0 20 40 60 80 100 120 1 10 100 1000 10000 Frequency of ADR TimetoonsetofADR Mapping safety & need for PhV Known at licensing • Pre-marketing data have important limitations • Pre-clinical data: low predictive value Clinical trial data provide provisional evidence of safety but: - too small - limited duration - limited populations - not representative of real world
  • 5. Establishment of drug safety monitoring
  • 6. Mitul Jadeja - EURODIS PV training Anything to do with a medicine I’ve been given that causes me harm ‘Suspected’ ADR or ‘side effect’ report to the national ADR reporting system What’s in a definition? • Adverse reaction; adverse drug reaction (ADR), Adverse effect, Undesirable effect: A response to a medicinal product which is noxious and unintended [DIR 2001/83/EC Art 1(11)]. Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility. Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure [DIR 2001/83/EC Art 101(1)]. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf&rct=j&frm=1&q=&esr c=s&sa=U&ved=0CBoQFjABahUKEwjolcC8yLzIAhUClA0KHXLNDOU&usg=AFQjCNHt2ArigMn1WpHp2KejiS76RDNYxA • GVP Module VI.B.6.3 -medication error: ‘any unintended error in the prescribing, dispensing or administration of a medicinal product while in the control of the healthcare professional, patient or consumer’ - this definition is focused on the management and reporting of adverse reactions to medicinal products and does not cover all stages of the medication use process where an error may occur and where there is an adverse reaction, e.g. preparation for administration. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000570.jsp
  • 7. Mitul Jadeja - EURODIS PV training Do you know your national medicines regulators? • EMA has a list of NCAs: http://www.ema.europa.eu/em a/index.jsp?curl=pages/medici nes/general/general_content_ 000155.jsp • National PV centres • RMCs
  • 8. Mitul Jadeja - EURODIS PV training www.adrreports.eu • Accessible in multiple languages • List of national medicines regulatory authorities in the EEA • Information on reporting • Access reports submitted to Eudravigilance • Like iDAPs • Online • App • clinical systems • Paper • phone Mitul Jadeja - EURODIS PV training
  • 9. Mitul Jadeja - EURODIS PV traininghttp://www.adrreports.eu/docs/ADR_reporting_FINAL_EN.pdf
  • 10. Mitul Jadeja - EURODIS PV training Black Triangle Scheme ▼ • Risk benefit profile knowledge limited - Report all ADRs • Materials: video and printable leaflets in many languages http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/genera l_content_000586.jsp&mid=WC0b01ac05807257a3 When does a medicine have a ▼? • new active substance; • biological medicine, such as a vaccine or a medicine derived from plasma (blood); • given a conditional approval (where the company that markets the medicine must provide more data about it) or approved under exceptional circumstances (where there are specific reasons why the company cannot provide a comprehensive set of data); • the company is required to carry out additional studies: for instance, to provide more data on long-term use of the medicine, or on a rare side effect seen during clinical trials. • Other medicines can also be placed under additional monitoring, based on a decision by the Agency's Pharmacovigilance Risk Assessment Committee (PRAC).
  • 11. Mitul Jadeja - EURODIS PV training Cystadrops (mercaptamine) • for treatment of cystinosis • typically diagnosed prior to age 2. • genetic metabolic disease that causes an amino acid, cystine, to accumulate in various organs of the body. Cystine crystals accumulate in the kidneys, eyes, liver, muscles, pancreas, brain, and white blood cells. • MA issued, +ve COMP opinion, Jan 17
  • 12. Mitul Jadeja - EURODIS PV training iDAP: interactive drug analysis profile
  • 13. Mitul Jadeja - EURODIS PV training Information on orphan designations
  • 14. Mitul Jadeja - EURODIS PV training Accessing outputs of regulatory action • Patient Safety warnings • Product information (MA): SmPCs & PILs, and labelling • EU Public Assessment Reports • Safety Communications e.g. Medicine Alerts and DHCPs • Rare disease designations • Pubic hearings • Committee information • Additional Monitoring lists • Risk Management Plans • Educational material – HPRA • Newsletters – e.g. Drug Safety Update • Sign up to updates and RSS feeds http://www.ema.europa.eu/ema/index.jsp?curl=p ages/home/Home_Page.jsp&mid=
  • 15. Mitul Jadeja - EURODIS PV training
  • 16. Mitul Jadeja - EURODIS PV training
  • 17. Mitul Jadeja - EURODIS PV training
  • 18. Mitul Jadeja - EURODIS PV training Pharmacovigilance legislation - ‘take all appropriate measures’ “Directive 2010/84/EU… Article 102. The Member States shall: ….take all appropriate measures to encourage patients, doctors, pharmacists and other health-care professionals to report suspected adverse reactions to the national competent authority [MHRA]; for these tasks, consumer organisations, patients organisations and healthcare professionals organisations may be involved as appropriate.” Preaching to the converted? Need to raise general awareness
  • 19. Mitul Jadeja - EURODIS PV training Responding to change: drivers for initiatives & campaigns – Protecting public health and patients – ADR statistics – Underreporting & impact of ADRs – pharmacovigilance legislation implications: • Definition of ADR • EU wide patient reporting • Additional Monitoring - ▼ • Support for strengthening ADR reporting; product information messages – HMA support: same 4 pillars – Independent review e.g. HTA, Avery report recommendations – Maintaining/strengthening ‘regularory position’ – SCOPE and ICMRA Directive 2010/84/EU and Regulation 1235/2010
  • 20. Mitul Jadeja - EURODIS PV training Patient Information Leaflet For medicinal products subject to additional monitoring ONLY: The black symbol and the statements should only appear immediately after the declaration of the name of the medicine. The black symbol shall be a black inverted equilateral triangle: the symbol shall be proportional to the font size of the subsequent standardised text and in any case each side of the triangle shall have a minimum length of 5 mm. For the purpose of preparing the product information annexes please use the Black Triangle as presented in the template. ‘▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.’ For ALL medicinal products: The following sub-heading should appear at the end of section 4 ‘Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.’
  • 21. Mitul Jadeja - EURODIS PV training Patient reporting in EV – a measure of patient engagement? Workshop on measuring the impact of PV activities • Patients are more likely to report ADRs for substances for genitourinary system and systemic hormonal preparations than HCPs – aligned with the results for Indications (2009-15) • 13/20 most frequently reported terms are identical as HCPs. • Marin Banovac 6/12/16
  • 22. KISSS – keep it simple, short and specific • Experienced a side effect? Please report!  • Always read the PIL (lists known side effects) • Speak to a healthcare professional for advice – Explain the benefit  & to public health – Don’t delay, report today ‐ don’t wait for someone else to  report it – Only a suspicion is needed, even if you • don’t see a connection between the drug & ADR • think the ADR doesn’t last for long, isn’t severe, or you think it‘s from  long term use • Don’t worry about ▼, off‐label use, med errors….. Avoid scare tactics Mitul Jadeja – EURODIS PV training 22
  • 23. Mitul Jadeja - EURODIS PV training Developing clear messages based on research Patients • Your report is important to help make medicines safer • Only a suspicion is needed to report • How to report • Always read the Patient Information Leaflet supplied with your medicine for more information on side effects • Speak to your HCP for further advice Parents • Reports from parents like you are very useful. • Parents know their child better than anyone and can tell us about things that healthcare professionals can’t. • We want parents to send reports even if they only have slight concerns about a medicine – you don’t need to be certain that a medicine has actually caused a side effect to send a report. • Reports are confidential. We won’t share the information on your report with your child’s doctor if you don’t want us to. Consider integrating the following set of key messages for developing basic patient messages for promotion purposes (from campaign material used):
  • 24. Mitul Jadeja - EURODIS PV training Proactive pyramid of engagement opportunities • Offer a menu to NCA’s • Empowerment vs Engagement • Consider: ‐ Budget ‐ Resource ‐ Time to engage ‐ Training ‐ Local vs national ‐ Helplines ‐ RMCs ‐ Registries ‐ MoUs ‐ Tenders Decision  making Consulting Committee & Management Research &  Project  work Social  media Forming  formalised  partnership  &   agreement Campaign  work – ADRs can  be the first  catalyst Educational  programmes Educational  materials
  • 25. Mitul Jadeja - EURODIS PV training EMA model
  • 26. Mitul Jadeja - EURODIS PV training What impact can engagement provide? • Patient/consumer perspective • Patient concerns/questions • Disease specific • Appropriate language – complicated, scientific terms, numbers, benefits, approval • Understandable without source docs • ‘Fresh eyes’ • Quality check • Enhanced communication • Effectiveness of messages • Better outcomes
  • 28. Mitul Jadeja - EURODIS PV training Where do you begin? Where are you now? Where do you want to be? How are you going to get there? (in relation to ADRs!)
  • 29. Mitul Jadeja - EURODIS PV training Where are you now? • ADR statistics – helps focus efforts – example tables in guidance • Stakeholder analysis – helps shape strategy & messages – basic stakeholder analysis matrix in guidance – Understand your audience • Benchmarking – focuses efforts, helps measure, an engagement opportunity – examples of through polls and surveys 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 patients pharmacists nurses doctors ‘Combined qualifications’ from ‘direct’ Yellow Cards reporting 2011 2012 2013 2014 2015 2016
  • 30. Benchmarking questions ADR reporting Who would you report an unexpected side effect with a medicine to? (Or ADR if aimed at HCPs) If a patient reports an ADR to you, to whom or to which organisation would you report it, if anyone? Which, if any, of the following things would help you to report ADRs? Medicines Regulation Who do you think regulates medicines to make sure they work and are safe enough to use? How much, if anything, would you say you know about the way medicines are regulated?
  • 31. Mitul Jadeja - EURODIS PV training Where do you want to be? • Across the national health service, where will you choose to raise awareness levels? Why?FocusFocus • What about patients? Their organisations?StakeholdersStakeholders • How is your work related with other organisations or regulators?InteractionsInteractions • What collaborations and partnerships can be formed?PartnershipsPartnerships • What do you need to implement your strategy?ImplementationImplementation • What does it look like? Can you compare before and after?Measuring successMeasuring success • What can you do once for a lasting impact on ADR reporting and your audiences?Sustainable effortsSustainable efforts
  • 32. Mitul Jadeja - EURODIS PV training What to measure? Real impact is the number of suspected ADR reports (consider measuring per population) • Outputs – e.g. numbers of posters, books, leaflets, posters, partnerships etc. • Key messages and out-takes – e.g. where to report, understanding of the concept of reporting, understanding the value of reporting, the effect of reporting, etc. • Outcomes – changes in suspected ADR reporting numbers, changes in behaviours, attitudes, opinions which can be measured. • Examples from: GR, SE, ES, IS, MT, NL, FR, HR, DK, UK
  • 33. Mitul Jadeja - EURODIS PV training Working with stakeholders • Improves the ability to reach target audience • Deliver messages effectively and reduces message fatigue • Provided potential additional opportunities • Feedback on approach and effectiveness • Cost effective – Regional PV centres – Academic organisations – Professional bodies – Hospitals – Charities/voluntary organisations – Government agencies
  • 34. ADR reports ADR reports monitor numbers before and after, consider per x population monitor numbers before and after, consider per x population dashboards, management reports dashboards, management reports SignalsSignals monitor numbers before and after monitor numbers before and after signal dashboards, PRAC signals, regulatory action signal dashboards, PRAC signals, regulatory action Attitudes and behaviour Attitudes and behaviour analyse changes before and after analyse changes before and after surveys, pols, interviews, workshops, focus groups, action plans surveys, pols, interviews, workshops, focus groups, action plans Social media Social media views, retweets, likes, shares, polls, follows, followers, blogs, RSS subscribers views, retweets, likes, shares, polls, follows, followers, blogs, RSS subscribers management reports, simple counts and software tools management reports, simple counts and software tools WebsiteWebsite web analytics to monitor trends over time, site search terms, downloads, views web analytics to monitor trends over time, site search terms, downloads, views analytical software such as Google analytics, Webtrends analytical software such as Google analytics, Webtrends Measuring success: 1) Key areas 2) what to measure 3) how to measure 1 2 3
  • 35. Mitul Jadeja - EURODIS PV training Key Activities
  • 36. Mitul Jadeja - EURODIS PV training Video and digital banners
  • 38. Mitul Jadeja - EURODIS PV training Challenges • Time taken to engage with stakeholders & continuing engagement • Multiple changes in staff • Negotiation and influencing – low/no cost • Measuring success - ‘some’ communications can be difficult to show any immediate cultural changes • Opinions and consensus - political • Press work & Patient case studies • Flexibility in approaches to working
  • 40. Mitul Jadeja - EURODIS PV training SCOPE guidance • Raising and Measuring Awareness Levels for ADR Reporting Systems through Campaigns and Regional Monitoring Centres • Contains huge annex of case studies by country containing materials • e.g. ANSM call for patients/organisations to report and get involved in studies Author: Mitul Jadeja
  • 41. Mitul Jadeja - EURODIS PV training SCOPE animation https://www.youtube.com/watch?v=3et5LdYLc8M
  • 42. Mitul Jadeja - EURODIS PV training Suspected side effect?
  • 43. Mitul Jadeja - EURODIS PV training • In UK, over 6K. • Pilot findings • Similar levels of reports of serious reactions • Fewer reactions to black triangle drugs • Less complete reports: but no difference in causality, or proportion of unlabelled reactions • More information on impact of ADRs on quality of life • Low levels of consumer awareness of the YC Scheme Reporting helps
  • 44. Mitul Jadeja - EURODIS PV training Essential Information 1. Suspect drug 2. Description of the side effect 3. Patient details (e.g. age, sex, weight) 4. Reporter details Additional Information • Relevant past medical history • Test results • Whether reaction was serious • Name and address of reporter • * GP details (patient’s consent required) Important Information • Dose and indication of the suspect drug and dates of the treatment • Dates the suspect reaction started and stopped • Outcome of the reaction • Other drugs taken in the past 3 months prior to the reaction Break down reporting
  • 45. Mitul Jadeja - EURODIS PV training Use this crib sheet to help complete a Yellow Card if you suspect an adverse drug reaction (ADR) Adverse Drug Reaction suspected? www.mhra.gov.uk/yellowcard or App Paper Yellow Cards available from: back of the BNF, MHRA Commission on Medicines (CHM) free phone: 0800 731 6789, ABPI medicines compendium or MIMS Companion Report it via a Yellow Card The minimum information needed for completing a Yellow Card: Additional information to supply (this information helps assess the Yellow Card): Names of the medicine(s) suspected to have caused the reaction Details of the suspect medicine(s) if available. For example; dose start and stop dates route of administration Batch numbers especially for vaccines, biosimilars and biological medicines action taken with the drug - stopped, dose change, restarted, none etc. Suspected reaction(s) Details of the reactions if available: a brief description of reaction diagnosis if relevant start and stop dates of reaction seriousness (use tick boxes on Yellow Card) treatment given reaction outcome At least one patient identifier:  Sex  Age  Weight  initials  local identifier All should be completed if available Any additional information you have: relevant medical history test results other drugs taken in the last 3 months if any rechallenge was performed If it is a congenital abnormality, state all other drugs taken during pregnancy and date of last menstrual period If no further information is available, please indicate this on the Yellow Card Reporter details: Include your name, qualification and full address Do you suspect an adverse drug reaction? Serious reaction? Involves a medicine on additional monitoring (▼)? Unlisted reaction in product information Unsure to report? No Involves a child or elderly person? ReportYes No No No No ReportYes ReportYes ReportYes ReportYes Other PDFs with info for patients on the Yellow Card website on what to report and why – applicable for all reporting systems.
  • 46. Mitul Jadeja - EURODIS PV training Case studies are important [Image from Arch Dis Child Fetal Neonatal Ed 2012;97:F64. doi:10.1136/adc.2011.215145] • chlorhexidine antiseptic solution associated with chemical burns • review of OTC liquid codeine medicines for cough in children • review of over-the-counter cough and cold medicines for use in children • oral iron products associated with hypersensitivity (allergic type reactions) • skin reactions associated with the use of aqueous cream in children with eczema • https://www.gov.uk/government/uploads/system/uploads/atta chment_data/file/396811/Contribution_of_Yellow_Cards_to_i dentifying_safety_issues.pdf
  • 47. Mitul Jadeja - EURODIS PV training
  • 48. Mitul Jadeja - EURODIS PV training
  • 49. Mitul Jadeja - EURODIS PV training Mobile Applications • Secure – no ADRs stored on device • View numbers of YCs • Simple to submit updates to reports • Allows viewing of previous reports via the app • WEB-RADR Mitul Jadeja - SCOPE EURODIS PV training
  • 50. Mitul Jadeja - EURODIS PV training Channels and Tactics highlighted Channels and Tactics highlighted Hungary Interactive presentations Hungary Interactive presentations Bulgaria posters and arguments list Bulgaria posters and arguments list Croatia Radio & Theatre Croatia Radio & Theatre Denmark Learning website with videos Denmark Learning website with videos Czech Republic Videos, postcards & posters Czech Republic Videos, postcards & posters Latvia PV book Latvia PV book United Kingdom online forum for doctors use of social media and digital banners United Kingdom online forum for doctors use of social media and digital banners Ireland Congress and special award Ireland Congress and special award Most successful campaigns featured: • forming long term sustainable partnerships • engagement with HCPs in a familiar environment • Distributed & online materials • Press & media coverage • Use of various forms of collateral and channels
  • 51. After these medicines, Doctor, I feel better already but my wife says I have a strange colour recently. Hepatotoxicity is a possible side effect of many medications
  • 52. Mitul Jadeja - EURODIS PV training Leaflets
  • 53. Mitul Jadeja - EURODIS PV training Videos from projects https://www.youtube.com/watch?v=cRLHFKuNQEc http://greatdanefilm.dk/web/laeger/20102011bivirkning/
  • 54. Mitul Jadeja - EURODIS PV training
  • 55. Mitul Jadeja - EURODIS PV training Special Populations
  • 56. Mitul Jadeja - EURODIS PV training WHO collateral
  • 57. Mitul Jadeja - EURODIS PV training • Maximising use of social media
  • 58. Mitul Jadeja - EURODIS PV training • Using hash tags & specificity • #PV • #drugsafety • #patientsafety • #ADRs • #reportsideeffects…
  • 59. Mitul Jadeja - EURODIS PV training • Leverage content across platforms to boost efficiency & avoid content duplication
  • 60. Mitul Jadeja - EURODIS PV training Take home messages • Be proactive to promote and report suspected ADRs with patients and your members. Social media is a powerful medium, use the ready to use materials available to support tackle underreporting and raising awareness. • Keep is simple, short and specific • Access regulatory outputs to engage with NCAs/patients • Don’t hesitate to ask/offer support/guidance on materials /decisions that you can input/develop/tailor to meet patient needs • Consider the engagement pyramid – how can you help NCAs understand your stakeholders and help shape direction of work and decision making
  • 61. Mitul Jadeja - EURODIS PV training Reflections… • When did you last discuss side effects with members? • Have you surveyed them? What are their awareness levels? ▼? Have you done a SWOT or GAP analysis? • How many side effects have you reported? How was the experience? Did you feedback? • What can you do to promote reporting? • What are your messages? • Which tools will you use? Are they the most effective? • How will you stay up to date with latest info? • How will you measure success? • Social media – how active are you? • Will you support future campaigns? Are you a patient QPPV? Contacted your regulator? • What else do you need to facilitate your important role in patient safety?
  • 62. Mitul Jadeja - EURODIS PV training Thank you and questions?
  • 63. Crown copyright 2018 • The views of the author are his own. • The materials featured within these MHRA presentation notes and delegate pack are subject to Crown copyright protection for this event. Any other copy or use of Crown copyright materials featured in this presentation, in any form or medium, is subject to prior approval of the MHRA which has Delegated Authority from Her Majesty's Stationery Office (HMSO) to administer Crown copyright for MHRA originated material. Applications should be in writing, clearly stating the proposed use/reuse of the information, and should be sent to the MHRA at the following address: Conference and Education Function 151 Buckingham Palace Road London SW1W 9SZ Fax 020 3080 6522 e-mail: speakers@mhra.gsi.gov.uk • You may not sell or resell any information reproduced to any third party without prior agreement. The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned